Skip to main content

Advertisement

SpringerLink
Log in

Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma

  • Short Communication
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Anti-idiotype monoclonal antibody (mAb) 1E10 was generated by immunizing BALB/c mice with an Ab1 mAb which recognizes NeuGc-containing gangliosides, sulfatides and some tumor antigens. 1E10 mAb induces therapeutic effects in a primary breast carcinoma and a melanoma model. However, the tumor immunity mechanisms have not been elucidated. Here we show that aluminum hydroxide-precipitated 1E10 mAb immunization induced anti-metastatic effect in the 3LL-D122 Lewis Lung carcinoma, a poorly immunogenic and highly metastatic model in C57BL/6 mice. The therapeutic effect was associated to the increment of T cells infiltrating metastases, the reduction of new blood vessels formation and the increase of apoptotic tumor cells in lung nodules. Interestingly, active immunization does not induce measurable antibodies to the 1E10 mAb, the NeuGc-GM3 or tumor cells, which may suggest a different mechanism which has to be elucidated. These findings may support the relevance of this target for cancer biotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

Abbreviations

Ag:

Antigen

Ab(s):

Antibodies

ELISA:

Enzyme-linked immunosorbent assay

Id:

Idiotype

mAb(s):

Monoclonal antibody(ies)

NeuGc:

Neu-glycolyl

sc:

Subcutaneous

References

  1. Jerne NK (1974) Towards a network theory of the immune system. Ann Immunol (Paris) 125C(1–2):373–389

    CAS  Google Scholar 

  2. Dunn PL, Johnson CA, Styles JM, Pease SS, Dean CJ (1987) Vaccination with syngeneic monoclonal anti-idiotype protects against a tumour challenge. Immunology 60(2):181–186

    PubMed  CAS  Google Scholar 

  3. Jinnohara T, Tsujisaki M, Sasaki S, Hinoda Y, Taniguchi M, Imai K (1998) Anti-tumor effect of internal image bearing anti-idiotypic monoclonal antibody in relation to GM3 ganglioside. Int J Cancer 76(3):345–353

    Article  PubMed  CAS  Google Scholar 

  4. Denton GW, Durrant LG, Hardcastle JD, Austin EB, Sewell HF, Robins RA (1994) Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 57(1):10–14

    Article  PubMed  CAS  Google Scholar 

  5. Durrant LG, Doran M, Austin EB, Robins RA (1995) Induction of cellular immune responses by a murine monoclonal anti-idiotypic antibody recognizing the 791Tgp72 antigen expressed on colorectal, gastric and ovarian human tumours. Int J Cancer 61(1):62–66

    Article  PubMed  CAS  Google Scholar 

  6. Fagerberg J, Steinitz M, Wigzell H, Askelof P, Mellstedt H (1995) Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 92(11):4773–4777

    Article  PubMed  CAS  Google Scholar 

  7. Durrant LG, Buckley DJ, Robins RA, Spendlove I (2000) 105Ad7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer patients but repeated immunisations are required to maintain these responses. Int J Cancer 85(1):87–92

    Article  PubMed  CAS  Google Scholar 

  8. Reinartz S, Kohler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Mobus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U (2004) Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 10(5):1580–1587

    Article  PubMed  CAS  Google Scholar 

  9. Vazquez AM, Alfonso M, Lanne B, Karlsson KA, Carr A, Barroso O, Fernandez LE, Rengifo E, Lanio ME, Alvarez C et al (1995) Generation of a murine monoclonal antibody specific for N-glycolylneuraminic acid-containing gangliosides that also recognizes sulfated glycolipids. Hybridoma 14(6):551–556

    PubMed  CAS  Google Scholar 

  10. Vazquez AM, Gabri MR, Hernandez AM, Alonso DF, Beausoleil I, Gomez DE, Perez R (2000) Antitumor properties of an anti-idiotypic monoclonal antibody in relation to N-glycolyl-containing gangliosides. Oncol Rep 7(4):751–756

    PubMed  CAS  Google Scholar 

  11. Alfonso M, Diaz A, Hernandez AM, Perez A, Rodriguez E, Bitton R, Perez R, Vazquez AM (2002) An anti-idiotype vaccine elicits a specific response to N-glycolyl sialic acid residues of glycoconjugates in melanoma patients. J Immunol 168(5):2523–2529

    PubMed  CAS  Google Scholar 

  12. Neninger E, Diaz RM, de la Torre A, Rives R, Diaz A, Saurez G, Gabri MR, Alonso DF, Wilkinson B, Alfonso AM, Combet T, Perez R, Vazquez AM (2007) Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 6(2):145–150

    PubMed  CAS  Google Scholar 

  13. Vazquez AM, Perez A, Hernandez AM, Macias A, Alfonso M, Bombino G, Perez R (1998) Syngeneic anti-idiotypic monoclonal antibodies to an anti-NeuGc-containing ganglioside monoclonal antibody. Hybridoma 17(6):527–534

    PubMed  CAS  Google Scholar 

  14. Hernandez AM, Rodriguez M, Lopez-Requena A, Beausoleil I, Perez R, Vazquez AM (2005) Generation of anti-Neu-glycolyl-ganglioside antibodies by immunization with an anti-idiotype monoclonal antibody: a self versus non-self-matter. Immunobiology 210(1):11–21

    Article  PubMed  CAS  Google Scholar 

  15. Diaz A, Alfonso M, Alonso R, Saurez G, Troche M, Catala M, Diaz RM, Perez R, Vazquez AM (2003) Immune responses in breast cancer patients immunized with an anti-idiotype antibody mimicking NeuGc-containing gangliosides. Clin Immunol 107(2):80–89

    Article  PubMed  CAS  Google Scholar 

  16. Chou HH, Takematsu H, Diaz S, Iber J, Nickerson E, Wright KL, Muchmore EA, Nelson DL, Warren ST, Varki A (1998) A mutation in human CMP-sialic acid hydroxylase occurred after the Homo-Pan divergence. Proc Natl Acad Sci USA 95(20):11751–11756

    Article  PubMed  CAS  Google Scholar 

  17. Ledeen RW, Yu RK (1982) Gangliosides: structure, isolation, and analysis. Methods Enzymol 83:139–191

    Article  PubMed  CAS  Google Scholar 

  18. Olson MV, Varki A (2003) Sequencing the chimpanzee genome: insights into human evolution and disease. Nat Rev Genet 4(1):20–28

    Article  PubMed  CAS  Google Scholar 

  19. Stults CL, Sweeley CC, Macher BA (1989) Glycosphingolipids: structure, biological source, and properties. Methods Enzymol 179:167–214

    Article  PubMed  CAS  Google Scholar 

  20. Eisenbach L, Hollander N, Greenfeld L, Yakor H, Segal S, Feldman M (1984) The differential expression of H-2 K versus H-2D antigens, distinguishing high-metastatic from low-metastatic clones, is correlated with the immunogenic properties of the tumor cells. Int J Cancer 34(4):567–573

    Article  PubMed  CAS  Google Scholar 

  21. Alfonso M, Vazquez AM, Carr A, Haerslev T, Fernandez LE, Lanio ME, Alvarez C, Zeuthen J, Perez R (1995) T cell-independent B cell response to self-monosialogangliosides: primary response monoclonal antibodies. Hybridoma 14(3):209–216

    Article  PubMed  CAS  Google Scholar 

  22. Kerbel RS (2000) Tumor angiogenesis: past, present and the near future. Carcinogenesis 21(3):505–515

    Article  PubMed  CAS  Google Scholar 

  23. Kohlgraf KG, Gawron AJ, Higashi M, VanLith ML, Shen X, Caffrey TC, Anderson JM, Hollingsworth MA (2004) Tumor-specific immunity in MUC1.Tg mice induced by immunization with peptide vaccines from the cytoplasmic tail of CD227 (MUC1). Cancer Immunol Immunother 53(12):1068–1084

    Article  PubMed  CAS  Google Scholar 

  24. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F, Jiang Y, Hu B, Wu Y, Su JM, Lou YY, He QM, Wen YJ, Yang JL, Kan B, Mao YQ, Luo F, Peng F (2003) Immunotherapy of tumors with vaccine based on quail homologous vascular endothelial growth factor receptor-2. Blood 102(5):1815–1823

    Article  PubMed  CAS  Google Scholar 

  25. Birebent B, Mitchell E, Akis N, Li W, Somasundaram R, Purev E, Hoey D, Mastrangelo M, Maguire H, Harris DT, Nair S, Cai D, Zhang T, Herlyn DM (2003) Monoclonal anti-idiotypic antibody mimicking the gastrointestinal carcinoma-associated epitope CO17–1A elicits antigen-specific humoral and cellular immune responses in colorectal cancer patients. Vaccine 21(15):1601–1612

    Article  PubMed  CAS  Google Scholar 

  26. Pride MW, Shuey S, Grillo-Lopez A, Braslawsky G, Ross M, Legha SS, Eton O, Buzaid A, Ioannides C, Murray JL (1998) Enhancement of cell-mediated immunity in melanoma patients immunized with murine anti-idiotypic monoclonal antibodies (MELIMMUNE) that mimic the high molecular weight proteoglycan antigen. Clin Cancer Res 4(10):2363–2370

    PubMed  CAS  Google Scholar 

  27. Wagner U, Kohler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Mobus V, Kreienberg R, Bauknecht T, Krebs D, Wallwiener D (2001) Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 7(5):1154–1162

    PubMed  CAS  Google Scholar 

  28. Livingston PO, Ragupathi G (1997) Carbohydrate vaccines that induce antibodies against cancer. 2. Previous experience and future plans. Cancer Immunol Immunother 45(1):10–19

    Article  PubMed  CAS  Google Scholar 

  29. Chapman PB (2003) Vaccinating against GD3 ganglioside using BEC2 anti-idiotypic monoclonal antibody. Curr Opin Investig Drugs 4(6):710–715

    PubMed  CAS  Google Scholar 

  30. Ishioka GY, Lamont AG, Thomson D, Bulbow N, Gaeta FC, Sette A, Grey HM (1992) MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol 148(8):2446–2451

    PubMed  CAS  Google Scholar 

  31. Shamshiev A, Donda A, Carena I, Mori L, Kappos L, De Libero G (1999) Self glycolipids as T-cell autoantigens. Eur J Immunol 29(5):1667–1675

    Article  PubMed  CAS  Google Scholar 

  32. Wu DY, Segal NH, Sidobre S, Kronenberg M, Chapman PB (2003) Cross-presentation of disialoganglioside GD3 to natural killer T cells. J Exp Med 198(1):173–181

    Article  PubMed  CAS  Google Scholar 

  33. Mazorra Z, Mesa C, Fernandez A, Fernandez LE (2008) Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge. Cancer Immunol Immunother 57(12):1771–1780

    Article  PubMed  CAS  Google Scholar 

  34. Guthmann MD, Castro MA, Cinat G, Venier C, Koliren L, Bitton RJ, Vazquez AM, Fainboim L (2006) Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients. J Immunother 29(2):215–223

    Article  PubMed  CAS  Google Scholar 

  35. Sasisekharan R, Shriver Z, Venkataraman G, Narayanasami U (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2(7):521–528

    Article  PubMed  CAS  Google Scholar 

  36. Rajotte D, Arap W, Hagedorn M, Koivunen E, Pasqualini R, Ruoslahti E (1998) Molecular heterogeneity of the vascular endothelium revealed by in vivo phage display. J Clin Invest 102(2):430–437

    Article  PubMed  CAS  Google Scholar 

  37. Perez A, Mier ES, Vispo NS, Vazquez AM, Perez Rodriguez R (2002) A monoclonal antibody against NeuGc-containing gangliosides contains a regulatory idiotope involved in the interaction with B and T cells. Mol Immunol 39(1–2):103–112

    Article  PubMed  CAS  Google Scholar 

  38. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70

    Article  PubMed  CAS  Google Scholar 

  39. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909–918

    Article  PubMed  CAS  Google Scholar 

  40. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011–1027

    Article  PubMed  CAS  Google Scholar 

  41. Klasa RJ, Gillum AM, Klem RE, Frankel SR (2002) Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 12(3):193–213

    Article  PubMed  CAS  Google Scholar 

  42. Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5):1028–1043

    Article  PubMed  CAS  Google Scholar 

  43. Amin S, Robins RA, Maxwell-Armstrong CA, Scholefield JH, Durrant LG (2000) Vaccine-induced apoptosis: a novel clinical trial end point? Cancer Res 60(12):3132–3136

    PubMed  CAS  Google Scholar 

  44. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, Frelinger JA, Robinson BW (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170(10):4905–4913

    PubMed  CAS  Google Scholar 

  45. Roque-Navarro L, Chakrabandhu K, de Leon J, Rodriguez S, Toledo C, Carr A, de Acosta CM, Hueber AO, Perez R (2008) Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity. Mol Cancer Ther 7(7):2033–2041

    Article  PubMed  CAS  Google Scholar 

  46. Crombet-Ramos T, Rak J, Perez R, Viloria-Petit A (2002) Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: a humanized anti-EGFR antibody. Int J Cancer 101(6):567–575

    Article  PubMed  CAS  Google Scholar 

  47. Jung YD, Mansfield PF, Akagi M, Takeda A, Liu W, Bucana CD, Hicklin DJ, Ellis LM (2002) Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model. Eur J Cancer 38(8):1133–1140

    Article  PubMed  CAS  Google Scholar 

  48. Komita H, Homma S, Saotome H, Zeniya M, Ohno T, Toda G (2006) Interferon-gamma produced by interleukin-12-activated tumor infiltrating CD8+ T cells directly induces apoptosis of mouse hepatocellular carcinoma. J Hepatol 45(5):662–672

    Article  PubMed  CAS  Google Scholar 

  49. Dorothee G, Vergnon I, Menez J, Echchakir H, Grunenwald D, Kubin M, Chouaib S, Mami-Chouaib F (2002) Tumor-infiltrating CD4+ T lymphocytes express APO2 ligand (APO2L)/TRAIL upon specific stimulation with autologous lung carcinoma cells: role of IFN-alpha on APO2L/TRAIL expression and -mediated cytotoxicity. J Immunol 169(2):809–817

    PubMed  CAS  Google Scholar 

  50. Manjili MH (2007) Come forth 1E10 anti-idiotype vaccine: delivering the promise to immunotherapy of small cell lung cancer. Cancer Biol Ther 6(2):151–152

    PubMed  CAS  Google Scholar 

  51. Alfonso S, Diaz RM, de la Torre A, Santiesteban E, Aguirre F, Perez K, Rodriguez JL, Barroso MD, Hernandez AM, Toledo D, Gabri MR, Alonso DF, Viada C, Gomez RE, Suarez E, Vazquez AM, Perez R, Macias AE (2007) 1E10 anti-idiotype vaccine in non-small cell lung cancer: experience in stage IIIb/IV patients. Cancer Biol Ther 6(12):1847–1852

    Article  PubMed  CAS  Google Scholar 

  52. Gasparini G, Longo R, Fanelli M, Teicher BA (2005) Combination of antiangiogenic therapy with other anticancer therapies: results, challenges, and open questions. J Clin Oncol 23(6):1295–1311

    Article  PubMed  CAS  Google Scholar 

  53. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16(8):2659–2671

    PubMed  CAS  Google Scholar 

  54. Teicher BA (1999) Potentiation of cytotoxic cancer therapies by antiangiogenic agents. Humana Press Inc, Totowa

    Google Scholar 

  55. Woude GF, Kelloff GJ, Ruddon RW, Koo HM, Sigman CC, Barrett JC, Day RW, Dicker AP, Kerbel RS, Parkinson DR, Slichenmyer WJ (2004) Reanalysis of cancer drugs: old drugs, new tricks. Clin Cancer Res 10(11):3897–3907

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

We thank Dr L.E. Fernández (Vaccine Department, Center of Molecular Immunology) for generously providing gangliosides. This study was supported by Recom-Bio S.L. and by the Cuban Government.

Author information

Authors and Affiliations

  1. Experimental Immunotherapy Department, Center of Molecular Immunology, P.O. Box 16040, Havana, 11600, Cuba

    Y. Diaz, A. Gonzalez, A. Lopez & E. Montero

  2. Research and Development, Center of Molecular Immunology, Havana, Cuba

    R. Perez

  3. Antibody Engineering Department, Center of Molecular Immunology, P.O. Box 16040, Havana, 11600, Cuba

    A. M. Vazquez

Authors
  1. Y. Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Gonzalez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Lopez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Perez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. M. Vazquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. E. Montero
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to E. Montero.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Diaz, Y., Gonzalez, A., Lopez, A. et al. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 58, 1117–1128 (2009). https://doi.org/10.1007/s00262-008-0634-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-008-0634-y

Keywords

Search

Navigation